AIMT:NSD-Aimmune Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 34.29

Change

-0.02 (-0.04)%

Market Cap

USD 2.25B

Volume

1.22M

Average Target Price

USD 27.14 (-20.86%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.91 (+1.46%)

USD69.69B 32.32 25.77
REGN Regeneron Pharmaceuticals, Inc

-4.15 (-0.73%)

USD63.99B 21.32 16.47
SGEN Seattle Genetics, Inc

-0.96 (-0.54%)

USD30.73B N/A N/A
MRNA Moderna, Inc

-0.95 (-1.38%)

USD27.16B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-2.44 (-2.09%)

USD25.55B 28.27 25.54
RPRX Royalty Pharma plc

+0.67 (+1.65%)

USD24.71B 33.37 9.15
GMAB Genmab A/S

+0.27 (+0.72%)

USD24.24B 25.60 2.90
BGNE BeiGene, Ltd

+7.49 (+2.94%)

USD23.25B N/A N/A
IMMU Immunomedics, Inc

-0.02 (-0.02%)

USD19.73B N/A N/A
INCY Incyte Corporation

+0.48 (+0.53%)

USD19.67B 47.64 35.20

ETFs Containing AIMT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.45% 50% F 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.45% 50% F 60% D-
Trailing 12 Months  
Capital Gain 50.59% 69% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.59% 69% D+ 83% B
Trailing 5 Years  
Capital Gain 41.17% 78% C+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.17% 77% C+ 63% D
Average Annual (5 Year Horizon)  
Capital Gain 15.63% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.63% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.64% N/A N/A N/A N/A
Risk Adjusted Return 38.46% N/A N/A N/A N/A
Market Capitalization 2.25B 85% B 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.44 11% F 9% F
Price / Cash Flow Ratio -11.49 68% D+ 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -149.17% 19% F 8% F
Return on Invested Capital -112.85% 21% F 8% F
Return on Assets -53.24% 13% F 4% F
Debt to Equity Ratio 39.44% 37% F 49% F
Technical Ratios  
Short Ratio 5.94 41% F 28% F
Short Percent 38.57% 1% F 6% F
Beta 1.69 39% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector